Who has been buying NeoImmuneTech stock?

4 distinct insiders have filed 1 disclosed insider purchases in NeoImmuneTech (950220), most recently on 2026-05-19. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does NeoImmuneTech have?

NeoImmuneTech has 1 buy-side and 8 sell-side disclosures on record, covering ₩125M ($87K) in total reported value, spanning 2025-01-03 to 2026-05-19.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

NeoImmuneTech 950220

Company

네오이뮨텍NeoImmuneTech

Insiders

Buys

Total Value

₩125M ($87K)

Avg Return

+16.30%

Last Filing

2026-05-19

NeoImmuneTech (950220) has 1 disclosed insider purchases and 8 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩125M ($87K) in reported transaction value. The earliest filing StockDrifts holds for NeoImmuneTech is dated 2025-01-03; the most recent is 2026-05-19. Across these filings the average return since disclosure is +16.30%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-05-19	SELL	주식병합	김태경 Taekyung Kim	CEO	-104.9K	₩2,505	+45.5%	₩263M ($182K)
2026-05-19	SELL	주식병합	제넥신 Genexine	-	-22.3M	₩2,505	+45.5%	₩55.9B ($38.8M)
2026-05-19	SELL	주식병합	남궁진 Namgoong Jin	Director of Operations Support	-61.3K	₩2,505	+45.5%	₩154M ($107K)
2026-05-19	SELL	주식병합	김태우 Taewoo Kim	Chief Financial Officer (CFO)	-76.6K	₩2,505	+45.5%	₩192M ($133K)
2026-05-13	BUY	Market Buy	김태경 Taekyung Kim	CEO	131.1K	₩566	-11.5%	₩74M ($52K)
2026-04-22	BUY	주식매수선택권	남궁진 Namgoong Jin	Director of Operations Support	995	₩511	+166.9%	₩508K ($353)
2025-09-17	BUY	유상신주취득	제넥신 Genexine	-	6.9M	₩849	-33.2%	₩5.9B ($4.1M)
2025-09-17	SELL	기타	제넥신 Genexine	-	-6.9M	₩849	+33.2%	₩5.9B ($4.1M)
2025-08-29	SELL	Market Sell	남궁진 Namgoong Jin	Director of Operations Support	-10.1K	-	-	-
2025-08-29	SELL	Market Sell	김태우 Taewoo Kim	Chief Financial Officer (CFO)	-28.5K	-	-	-
2025-08-28	SELL	Market Sell	남궁진 Namgoong Jin	Director of Operations Support	-10.0K	-	-	-
2025-08-27	SELL	Market Sell	남궁진 Namgoong Jin	Director of Operations Support	-25.0K	-	-	-
2025-08-27	SELL	Market Sell	김태우 Taewoo Kim	Chief Financial Officer (CFO)	-30.0K	-	-	-
2025-08-25	SELL	Market Sell	김태우 Taewoo Kim	Chief Financial Officer (CFO)	-5.0K	-	-	-
2025-08-25	SELL	Market Sell	남궁진 Namgoong Jin	Director of Operations Support	-5.0K	-	-	-
2025-08-20	SELL	장외매도	제넥신 Genexine	-	-6.9M	₩1,008	+43.8%	₩7.0B ($4.9M)
2025-08-13	BUY	기타	제넥신 Genexine	-	13.9M	₩1,155	-50.9%	₩16.0B ($11.1M)
2025-08-13	BUY	기타	주지영 Joo Ji-young	Chief Manufacturing Officer (CMO)	36.5K	₩1,155	-50.9%	₩42M ($29K)
2025-08-13	BUY	기타	남궁진 Namgoong Jin	Director of Operations Support	50.1K	₩1,155	-50.9%	₩58M ($40K)
2025-08-13	BUY	기타	김태우 Taewoo Kim	Chief Financial Officer (CFO)	63.5K	₩1,155	-50.9%	₩73M ($51K)
2025-01-03	SELL	Market Sell	최동훈 Choi Dong-hoon	Chief Technology Officer (CTO)	-50.0K	₩1,014	+44.1%	₩51M ($35K)

Frequently asked questions

Who has been buying NeoImmuneTech stock?: 4 distinct insiders have filed 1 disclosed insider purchases in NeoImmuneTech (950220), most recently on 2026-05-19. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does NeoImmuneTech have?: NeoImmuneTech has 1 buy-side and 8 sell-side disclosures on record, covering ₩125M ($87K) in total reported value, spanning 2025-01-03 to 2026-05-19.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.